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Carrageenan induced edemaa b s t r a c t
The aim of this study was to synthesize three nitro substituted chalcones and to evaluate their anti-
inﬂammatory activity in the model of carrageenan induced edema in rats. The nitro chalcone were pre-
pared by aldol condensation using of mechanical agitation and environmentally friendly solvents with
72–73% yields in approximately 2 h. The three structures were evaluated on biological activity at dose
of 200 mg/kg and they showed anti-inﬂammatory protective effect by both oral and intraperitoneal
administration, this effect was time dependent.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Chalcones are part of the selected group of chemical compounds
associated with diverse pharmacological activities. The chalcone
structure has been reported in compounds with anti-inﬂamatory,
anti-ulcerative, antibacterial, antifungal and antimalarial activities
among others.1–5
Chalcones and their derivatives are polyphenolic compounds of
the ﬂavonoids family. They have been found in many plants as
metabolic precursors of other ﬂavonoids and isoﬂavonoids.6 It is
noteworthy to mention that the presence of chalcones have been
reported in plants traditionally employed for therapeutical
purposes.7,8
From a synthetic point of view, there is a great interest for the
development of structural analogues of chalcones.8 The Claisen–
Schmidt condensation between acetophenone derivatives with
benzaldehyde derivatives, with both acid and basic catalysis has
been by far the leading reaction employed for these compounds,
as shown in Figure 1.9
Furthermore, the synthesis of new chalcone analogues is grow-
ing nowadays, because of the potential anti-inﬂammatory activi-
ties they may exhibit, which make them attractive candidates for
the treatment of chronic diseases which involve inﬂammatory pro-
cesses, for example, diabetes mellitus.10
On behalf of this, the objectives of this work were to synthesize
three nitro-substituted chalcones and to evaluate theiranti-inﬂammatory activity in the carrageenan induced paw edema
model in rat.
The synthesis of the three nitro-chalcones was conducted by
the Claisen–Schmidt condensation between 20-nitroacetophenone
(1), 30-nitroacetophenone (2) and 40-nitroacetophenone (3) and
benzaldehyde (4), this reaction was promoted wit sodium hydrox-
ide (NAOH) according to previously reported procedure11 (Fig. 2).
All the reagents were analytical-reagent grade and were used
without further puriﬁcation. The general procedure started with
the preparation of a solution of NaOH (6.7 mmol) in water
(6 mL). This solution was cooled at 0 C with an ice bath, and
ethanol (10 mL) was slowly added, the reaction ﬂask was then
removed from the ice bath and set at room temperature before
the slow addition of the corresponding acetophenone (10 mmol)
after this, benzaldehyde (10 mmol) was slowly added to the reac-
tion mixture, which was left at room temperature with mechanical
agitation for 2 h, afterwards the reaction mixture was cooled at
0 C for 24 h. The solid products were ﬁltrated from the crude mix-
ture, washed with cold water and recrystallized with a dichloro-
methane/ethanol mixture. The crystals thus obtained were dried
at 70 C and properly stored at room temperature prior their
physicochemical and spectroscopic characterizations and the
determination of their anti-inﬂammatory activity. The chalcones
prepared with this procedure were: (E)-1-(20-nitrophenyl)-3-
phenylprop-2-en-1-one (20-nitrochalcone) (5); (E)-1-(30-nitro-
phenyl)-3-phenylprop-2-en-1-one (30-nitrochalcone) (6) and
(E)-1-(40-nitrophenyl)-3-phenylprop-2-en-1-one (40-nitrochalcone)
(7).
The three chalcones were obtained in good yields (>75%). All of
them were solids and they were poorly soluble in water and highly
Figure 1. Claisen–Schmidt condensation employed for the synthesis of chalcones.
Figure 3. Time course of the volume of the right rear paw of the rat: a rise of the
volume after the i.pl. application of carrageenan 0.3% is shown. Each point
represents average ± standard error (n = 6).
Figure 2. Synthesis of the three nitro-sustituted chalcones. (1) 20-Nitroacetophenone; (2) 30-nitroacetophenone; (3) 40-nitroacetophenone; (4) benzaldehyde; (5) 20-
nitrochalcone; (6) 30-nitrochalcone; (7) 40-nitrochalcone.
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the expected maximum absorbance wavelengths, whereas the IR
spectra bands were in agreement with the functional groups ex-
pected in the structures. The 1H NMR coupling constants for the
alquene protons, showed that the stereochemistry around the dou-
ble bond was (E) in the three compounds. The assignment of the
13C NMR spectra conﬁrmed the structures (Supplementary data).
The evaluation of the anti-inﬂammatory effect of the three chal-
cones was assayed by the carrageenan induced paw edema in rat.12
First, it was assayed the temporal evolution of the inﬂammatory
activity of carrageenan: 2 groups of 6 male Wistar rats (180–220 g)
were employed. At t = 0, the volume of the right hind paw was
measured. After this, one group was applied via intraplantar
(i.pl.) in the right hind paw with a single dose (50 lL) of carra-
geenan at 0.3% in saline solution 0.9%. The second group served
as control and was applied i.pl. in the right hind paw with a single
dose (50 lL) of saline solution 0.9%. The volume of the right hind
paw of the 12 specimens was measured every hour for 7 h. Each
measurement was made in triplicate with a pletismometer (Ugo
Basile 7140). The i.pl. application of carrageenan in the right hind
paw of the rats derived into an edema development from a basal
value of 1.1 ± 0.01 mL to a maximum of 1.9 ± 0.04 mL which was
presented 3 h after the administration of carrageenan. The control
group showed a basal volume of 1.1 ± 0.01 mL and there were no
statistical signiﬁcance differences (p <0.05) in the volume of the
control group along the 7 h of the experiment (Fig. 3). When the
volumes of the carrageenan and control groups were compared,
statistical signiﬁcance differences (p <0.05) were found.
The anti-inﬂammatory protective effect of the three chalcones
(5–7) was evaluated at a single dose of 200 mg kg1, the vehicle
employed was DMSO. To perform this test, an arrangement of 7groups, each of them with 6 rats, was made. Three of these groups
received their corresponding chalcone by oral administration
(p.o.), while other three received their corresponding chalcone by
intraperitoneal injection (ip). The seventh group was the control
and only received the vehicle p.o. Meloxicam (8) was employed
as a reference drug: a group of 6 rats received p.o. a single dose
(10 mg kg1) of the reference.13 After this administrations, a single
dose of carrageenan 0.3% vas applied i.pl. in the right hind paw of
each specimen, in a similar way as described above. The volume of
Figure 5. AUC for the MAPE of chalcones 5, 6 and 7 (200 mg kg1, p.o.) and the
reference drug 8 (10 mg kg1, p.o.) Each bar represents the average ± standard
deviation (n = 6). ⁄Statistically signiﬁcant difference (p <0.05).
Figure 6. Time course of the MAPE of chalcones 5, 6 and 7 (200 mg kg1, ip) and the
reference drug 8 (10 mg kg1, p.o.) on the carregeenan induced paw edema in rats.
Each point represents the average ± standard deviation (n = 6).
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7 h, employing the pletismometer technique.
For each animal, theMaximumAnti-inﬂammatory Protective Ef-
fect (MAPE) was calculated every hour during the length of the
experiment. MAPE was calculated as a percentage, according to
the following equation:MAPE(%) = [(VcarrVtreat)/(VcarrVo)]-
⁄[100]Where:Vcarr = volume of the rear paw of the rat which re-
ceived carrageenan i.pl.Vtreat = volume of the rear paw of the rat
who received either meloxicam or chalcone prior the application
of carrageenan.Vo = volume of the rear paw of the rat at zero time.14
The results for the MAPE are presented as the average ± stan-
dard deviation. In order to compare the differences between the
experimental groups, an ANOVA a Tukey Test and a Contrast Anal-
ysis were performed. Results were considered statistically signiﬁ-
cant at p <0.05.
Figure 4 show that the oral administration of every tested
chalcone, at a single oral dose of 200 mg kg1, produced an anti-
inﬂammatory protective effect which is time-dependent. For com-
pound 2, the maximum anti-inﬂammatory effect (34.8 ± 2.5%) was
obtained 3 h after the administration and the anti-inﬂammatory
effect was maintained in around 30% during the rest of the exper-
iment. For compound 3 the maximum effect (31.0 ± 5.6%) was
reached 2 h after the administration, but it began to diminish
one hour later to reach values near zero 7 h after the administra-
tion. For compound 4, the highest protective effect (38.0 ± 6.3%)
was reached one hour after de administration, it diminished at
around 20% 2 h after the administration and remained steady
during the next 6 h. For the reference group (compound 8) the
maximum effect (59.3 ± 3.8%) was reached within 2 h after the
administration, and remained steady (around 50–60%) during the
7 h of the experiment.
The area under the curve (AUC) for the temporal evolution of
the anti-inﬂammatory protective effect of each chalcone and the
reference drug administered p.o. were also calculated and the re-
sults are presented in Figure 5. The highest AUC corresponds to
compound 5 (303.71 ± 34.32), whereas compound 6 has the lowest
AUC (137.26 ± 16.82). The Tukey Test applied for the AUC values,
showed that the differences between the AUC’s and therefore the
differences in the anti-inﬂammatory protective effect of each
tested chalcone, are statistically signiﬁcant at p <0.05. Compound
5 (with the nitro group at the ortho position), developed the high-
est protective anti-inﬂammatory effect, while compound 6 (with
the nitro group at themeta position), showed the lowest protective
anti-inﬂammatory effect. When compared the AUC values of theFigure 4. Time course of the MAPE of chalcones 5, 6 and 7 (200 mg kg1, p.o.) and
the reference drug 8 (10 mg kg1, p.o.) on the carregeenan induced paw edema in
rats. Each point represents the average ± standard deviation (n = 6).three tested chalcones versus the reference drug 8, it was found
a statistically signiﬁcant difference at p <0.05, being meloxicam
the compound with the best anti-inﬂammatory protective effect.
On the other hand, the intraperitoneal administration of the
three nitro-substituted chalcones showed anti-inﬂammatory pro-
tective effects which were all time-dependent (Fig. 6). For com-
pound 5 the maximum effect (58.2 ± 3.2%) was reached 1 h after
the administration. The MAPE for 5 was maintained between 50%
and 60% during the 7 h of the experiment. Compound 6 recorded
the highest MAPE for the three chalcones (68.0 ± 3.8%) and it was
reached within the ﬁrst hour of the experiment, although 5 h after
the administration. Compound 7 reached its highest MAPE 2 h
after the administration (43.2 ± 3.3%), this effect was maintained
steady along the experiment. The highest MAPE for the reference
drug 8 (59.3 ± 3.8%) was reached 2 h after the administration and
it was maintained steady during the 7 h of the experiment.
The AUC for the temporal evolution of the anti-inﬂammatory
protective effect of each chalcone and the reference drug adminis-
tered ip were also calculated and the results are presented in Fig-
ure 7. As occurred in the oral administration, compound 5 also
showed the highest AUC (378.08 ± 32.34), but unlike the former
procedure, it was compound 7 and not 6 the one with the smallest
AUC (246.78 ± 36.8). The application of the Tukey test over the AUC
values showed statistically signiﬁcant differences when the AUC of
Figure 7. AUC for the MAPE of chalcones 5, 6 and 7 (200 mg kg1, ip) and the
reference drug 8 (10 mg kg1, p.o.) Each bar represents the average ± standard
deviation (n = 6). ⁄Statistically signiﬁcant difference (p <0.05). (+) No statistically
signiﬁcant difference was found.
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found that the chalcone 5, whith the nitro group at the ortho posi-
tion, develops the highest MAPE and the chalcone 7, with the nitro
group at the para position, showed the smallest MAPE effect. These
results, combined with those obtained for the oral administration
lead to state that the nitro group located at the ortho position plays
an important role in both the anti-inﬂammatory protective effect
and the bioavailability of chalcone 5.
Chalcones 6 and 7, also showed statistically signiﬁcant differ-
ences when compared with the reference drug, nevertheless it
was not found a statistically signiﬁcant difference between the
AUC of the MAPE for chalcone 5 and the corresponding value for
the reference drug.
The statistical contrast of the anti-inﬂammatory protective ef-
fect of 5, 6 and 7 administered at the same dose either orally or
by the intraperitoneal route, showed that the effect is different
and it depends on the route of administration, the latter being
the most suitable in order to generate a protective effect against
inﬂammation in the model employed.
In conclusion, three nitro-chalcones (5, 6 and 7) were synthe-
sized, employing shorter reaction times than the previouslyreported in the literature. The spectroscopic characterizations of
the three products are in agreement with the structures expected.
These chalcones showed an anti-inﬂammatory protective effect
when administered orally or by the intraperitoneal route. The chal-
cone with the nitro group at the ortho position was found to be the
most effective, with no statistically signiﬁcant difference when
compared to a reference drug (meloxicam).
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